Literature DB >> 19822712

Decreased clinical response to adalimumab in ankylosing spondylitis is associated with antibody formation.

M K de Vries, E Brouwer, I E van der Horst-Bruinsma, A Spoorenberg, J C van Denderen, A Jamnitski, M T Nurmohamed, B A C Dijkmans, L A Aarden, G J Wolbink.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19822712     DOI： 10.1136/ard.2009.109702

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  26 in total

Review 1.  Clinical pharmacology considerations in biologics development.

Authors:  Liang Zhao; Tian-hua Ren; Diane D Wang
Journal:  Acta Pharmacol Sin       Date:  2012-09-24       Impact factor: 6.150

Review 2.  Preclinical models used for immunogenicity prediction of therapeutic proteins.

Authors:  Vera Brinks; Daniel Weinbuch; Matthew Baker; Yann Dean; Philippe Stas; Stefan Kostense; Bonita Rup; Wim Jiskoot
Journal:  Pharm Res       Date:  2013-05-07       Impact factor: 4.200

3.  IgG4 production against adalimumab during long term treatment of RA patients.

Authors:  Pauline A van Schouwenburg; Charlotte L Krieckaert; Michael Nurmohamed; Margreet Hart; Theo Rispens; Lucien Aarden; Diana Wouters; Gerrit Jan Wolbink
Journal:  J Clin Immunol       Date:  2012-05-24       Impact factor: 8.317

4.  Clinical relevance of monitoring serum adalimumab levels in axial spondyloarthritis.

Authors:  José Miguel Senabre Gallego; Jose Rosas; Mariana Marco-Mingot; José Alberto García-Gómez; Gregorio Santos-Soler; Esteban Salas-Heredia; Ana Pons-Bas; Xavier Barber-Vallés; José Antonio Bernal-Vidal; Catalina Cano-Pérez; Mario García-Carrasco; Emilio Flores-Pardo
Journal:  Rheumatol Int       Date:  2019-03-21       Impact factor: 2.631

5.  Recombinant murine growth hormone particles are more immunogenic with intravenous than subcutaneous administration.

Authors:  Merry Christie; Raul M Torres; Ross M Kedl; Theodore W Randolph; John F Carpenter
Journal:  J Pharm Sci       Date:  2013-11-25       Impact factor: 3.534

Review 6.  Developments in therapies for spondyloarthritis.

Authors:  Joachim Sieper
Journal:  Nat Rev Rheumatol       Date:  2012-04-10       Impact factor: 20.543

Review 7.  Functional analysis of the anti-adalimumab response using patient-derived monoclonal antibodies.

Authors:  Pauline A van Schouwenburg; Simone Kruithof; Christian Votsmeier; Karin van Schie; Margreet H Hart; Rob N de Jong; Esther E L van Buren; Marieke van Ham; Lucien Aarden; Gertjan Wolbink; Diana Wouters; Theo Rispens
Journal:  J Biol Chem       Date:  2014-10-17       Impact factor: 5.157

8.  Practical application of acid dissociation in monitoring patients treated with adalimumab.

Authors:  Francisca Llinares-Tello; José Rosas-Gómez de Salazar; José Miguel Senabre-Gallego; Gregorio Santos-Soler; Carlos Santos-Ramírez; Esteban Salas-Heredia; Xavier Barber-Vallés; Juan Molina-García
Journal:  Rheumatol Int       Date:  2014-05-10       Impact factor: 2.631

Review 9.  Immunogenicity and loss of response to TNF inhibitors: implications for rheumatoid arthritis treatment.

Authors:  Joachim R Kalden; Hendrik Schulze-Koops
Journal:  Nat Rev Rheumatol       Date:  2017-11-21       Impact factor: 20.543

Review 10.  The effect of immunomodulators on the immunogenicity of TNF-blocking therapeutic monoclonal antibodies: a review.

Authors:  Charlotte Louise Maria Krieckaert; Geertje Margret Bartelds; Willem Frederik Lems; Gerrit Jan Wolbink
Journal:  Arthritis Res Ther       Date:  2010-10-20       Impact factor: 5.156
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.